The limitations of clinical signs and microbial techniques for the diagnosis of bacterial infections are eminent. The use of novel biomarkers, such as Procalcitonin and ProADM, provides a promising novel approach to better diagnose infection, antibiotic stewardship and early prognostication. Measurement of procalcitonin embedded in clinical algorithms can significantly improve the diagnostic certainty and safety of patients, and still reduce the (over-) utilization of antimicrobial therapy. Similarly, ProADM a prognostic biomarker, helps to reduce length of hospital stays by improving early risk assessment in respiratory infections. This tool provides physicians and researcher with uptodate algorithms for real time use of procalcitonin and ProADM in patients with respiratory infections and displays expected mortality and complications rate, as well as expected risks for bacteremia based on recent large scale trials.